Article Sidebar
Views pdf: 80
THE EFFECTIVENESS OF CETUXIMAB COMBINED WITH CHEMOTHERAPY IN FIRST - LINE TREATMENT FOR METASTATIC, RECURENCED COLORECTAL CANCER
Main Article Content
Abstract
The study aimed to evaluate the effectiveness and side effects of cetuximab combined with chemotherapy in first-line treatment for patients having metastatic or recurenced RAS wild-type colorectal cancer. Subjects and methods: A retrospective, descriptive study on 50 patients with metastatic or recurenced RAS wild-type colorectal cancer treated by cetuximab in combination with mFOLFOX6 or FOLFIRI in K hospital from 1/2017 to 3/2023. Results: The overall response rate (ORR) was 80%, the mean progression-free survival (PFS) was 15,1 months. The most common side effect was dermatitis acneiform (88%), in which grade 1-2 accounted for 84%; the nail changes occurred in 64% of the patients; the other side effects were mainly mild (grade 1-2). Conclusion: First-line cetuximab combined with chemotherapy resulted in high response rate and tolerable toxicity, which can be optimal treatment for patients with metastatic or recurenced RAS wild-type colorectal cancer.
Article Details
Keywords
: Cetuximab, metastatic colorectal cancer, RAS wild-type, first - line treatment.
References
2. Algars A., Lintunen M., and O., Carpen (2011), “EGFR gene copynumber assessment from area with highest EGFR expression predicts reasonse to anti- GFR therapy in colorectal cancer”, Br J cancer , 105. P255.
3. Fausto Petrellia., Raffaele Arditob (2018). “Different Toxicity of Cetuximab and Panitumumab in Metastatic ColorectalCancer Treatment A Systematic Review and Meta-Analysis” Oncology 1-9.
4. E. Van Cutsem (2010) Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome.
5. Đỗ Huyền Nga (2018) Đánh giá kết quả hóa trị phác đồ FOLFOX4 kết hợp bevacizumab trong ung thư đại trực tràng di căn, Luận án tiến sĩ y học, Đại Học Y Hà Nội
6. Heinneman V, von Weikersthal LF.,Decker T., “FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer” (FIRE-3), Lancet Oncol. 2014; 15: 1065-1075.
7. Huy TL (2017), "Nghiên cứu kết quả điều trị ung thư đại tràng di căn bằng hóa chất phác đồ FOFOXILI", Luận án tiến sỹ Y học, Đại học Y hà Nội., pp.
8. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta OncolStockhSwed.2014;53(7):852-864. doi:10.3109/0284186X.2014.895036.